Abstract：
In Italy Rotavirus vaccination (RVV) is provided free of charge from 2018, however, the coverage is scattered and suboptimal. The narrow time frame to complete the schedule is a barrier to uptake, and co-administration with other vaccines may potentially increase the coverage. Although the co-administration of RV vaccine and Meningococcal Group B vaccine (MenB) is not included in the product labels, we aimed at studying its impact on RVV coverage.
This Surveillance study on Timing and cOverage of Rotavirus and MenB vaccine co-administration (STORM study) used the Regional Vaccination Registry to collect data about children born in Campania Region between January 2016 and December 2020, and receiving vaccines scheduled in the first year of life.
Among the 224,110 children enrolled, 60,614 (27.0%) completed the RVV schedule, with a vaccination rate that increased over time from 1.15% in 2016 to 56.92% in 2020. The first and last dose of RVV schedule were administered beyond the recommended time in 6% of the study population, respectively. Co-administration of RV vaccine with MenB vaccine increased from 0.7 % in 2016 to 46.85 % in 2020. Children receiving RV/MenB vaccines concomitantly had a significantly higher chance of completing the RV schedule compared to those receiving RVV alone during a specific appointment (94.78 % vs 72.26 %, Prevalence Ratio -PR- 1.275, 95 %CI 1.245-1.295p < 0.00001). The positive driving effect of RV/MenB co-administration was more evident for children receiving pentavalent (PR 1.288) than monovalent RVV (PR 1.115) which was confirmed when adjusted for confounding variables (i.e., year of vaccination, local district, gender).
Although still far from the target, RVV coverage has increased in recent years in Campania Region. Co-administration with MenB vaccine may aid in increasing RVV coverage, especially for pentavalent RVV. Further safety data are needed to support co-administration as a key tool to increase coverage.
This Surveillance study on Timing and cOverage of Rotavirus and MenB vaccine co-administration (STORM study) used the Regional Vaccination Registry to collect data about children born in Campania Region between January 2016 and December 2020, and receiving vaccines scheduled in the first year of life.
Among the 224,110 children enrolled, 60,614 (27.0%) completed the RVV schedule, with a vaccination rate that increased over time from 1.15% in 2016 to 56.92% in 2020. The first and last dose of RVV schedule were administered beyond the recommended time in 6% of the study population, respectively. Co-administration of RV vaccine with MenB vaccine increased from 0.7 % in 2016 to 46.85 % in 2020. Children receiving RV/MenB vaccines concomitantly had a significantly higher chance of completing the RV schedule compared to those receiving RVV alone during a specific appointment (94.78 % vs 72.26 %, Prevalence Ratio -PR- 1.275, 95 %CI 1.245-1.295p < 0.00001). The positive driving effect of RV/MenB co-administration was more evident for children receiving pentavalent (PR 1.288) than monovalent RVV (PR 1.115) which was confirmed when adjusted for confounding variables (i.e., year of vaccination, local district, gender).
Although still far from the target, RVV coverage has increased in recent years in Campania Region. Co-administration with MenB vaccine may aid in increasing RVV coverage, especially for pentavalent RVV. Further safety data are needed to support co-administration as a key tool to increase coverage.
摘要：
背景：在意大利，从2018年开始免费提供轮状病毒疫苗接种（RVV），但是，覆盖率分散且次优。完成时间表的狭窄时间框架是吸收的障碍，与其他疫苗共同给药可能会增加覆盖率。尽管RV疫苗和脑膜炎球菌B组疫苗（MenB）的共同给药不包括在产品标签中，我们旨在研究其对RVV覆盖率的影响。
方法：这项关于轮状病毒和MenB疫苗共同给药的时间和寿命的监测研究（STORM研究）使用区域疫苗注册中心收集了有关2016年1月至2020年12月在坎帕尼亚地区出生的儿童的数据。
结果：在224,110名儿童中，60,614（27.0%）完成了RVV时间表，随着时间的推移，疫苗接种率从2016年的1.15%上升到2020年的56.92%。在6％的研究人群中，首次和最后一次剂量的RVV方案超过推荐时间，分别。RV疫苗与MenB疫苗的联合使用从2016年的0.7％增加到2020年的46.85％。与在特定预约期间仅接受RVV的儿童相比，同时接受RV/MenB疫苗的儿童完成RV时间表的机会明显更高（94.78％vs72.26％，患病率比率-PR-1.275，95CI1.245-1.295p<0.00001)。对于接受五价（PR1.288）的儿童，RV/MenB共同给药的积极驱动作用比一价RVV（PR1.115）更明显，这在校正混杂变量时得到了证实（即，接种疫苗的年份，当地区,性别)。
结论：尽管离目标还很远，近年来，坎帕尼亚地区的RVV覆盖率有所增加。与MenB疫苗共同施用可能有助于增加RVV覆盖率，尤其是五价RVV。需要进一步的安全性数据来支持共同管理，作为增加覆盖率的关键工具。
方法：这项关于轮状病毒和MenB疫苗共同给药的时间和寿命的监测研究（STORM研究）使用区域疫苗注册中心收集了有关2016年1月至2020年12月在坎帕尼亚地区出生的儿童的数据。
结果：在224,110名儿童中，60,614（27.0%）完成了RVV时间表，随着时间的推移，疫苗接种率从2016年的1.15%上升到2020年的56.92%。在6％的研究人群中，首次和最后一次剂量的RVV方案超过推荐时间，分别。RV疫苗与MenB疫苗的联合使用从2016年的0.7％增加到2020年的46.85％。与在特定预约期间仅接受RVV的儿童相比，同时接受RV/MenB疫苗的儿童完成RV时间表的机会明显更高（94.78％vs72.26％，患病率比率-PR-1.275，95CI1.245-1.295p<0.00001)。对于接受五价（PR1.288）的儿童，RV/MenB共同给药的积极驱动作用比一价RVV（PR1.115）更明显，这在校正混杂变量时得到了证实（即，接种疫苗的年份，当地区,性别)。
结论：尽管离目标还很远，近年来，坎帕尼亚地区的RVV覆盖率有所增加。与MenB疫苗共同施用可能有助于增加RVV覆盖率，尤其是五价RVV。需要进一步的安全性数据来支持共同管理，作为增加覆盖率的关键工具。
